Seladelpar
 | |
| Clinical data | |
|---|---|
| Trade names | Livdelzi |
| Other names | MBX-8025; RWJ-800025 |
| AHFS/Drugs.com | Livdelzi |
| License data |
|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H23F3O5S |
| Molar mass | 444.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Seladelpar, sold under the brand name Livdelzi, is a medication used for the treatment of primary biliary cholangitis.[1] It is used as the lysine dihydrate salt.[1] It is a peroxisome proliferator-activated receptor delta (PPARδ) receptor agonist.[1][2][3] The compound was licensed from Janssen Pharmaceutica NV.[4]
Seladelpar was approved for medical use in the United States in August 2024.[5][6]
Medical uses
[edit]Seladelpar is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable to tolerate ursodeoxycholic acid.[1]
Clinically, seladelpar reduces pruritus (itching) and interleukin-31 in people with primary biliary cholangitis.[7]
Society and culture
[edit]Legal status
[edit]In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Seladelpar Gilead, intended for the treatment of primary biliary cholangitis.[8] The applicant for this medicinal product is Gilead Sciences Ireland UC.[8]
The EMA granted seladelpar orphan medicine designation.[8]
Names
[edit]Seladelpar is the international nonproprietary name.[9]
References
[edit]- ^ a b c d e "Livdelzi- seladelpar lysine capsule". DailyMed. 14 August 2024. Retrieved 5 September 2024.
- ^ Billin AN (October 2008). "PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home". Expert Opinion on Investigational Drugs. 17 (10): 1465–1471. doi:10.1517/13543784.17.10.1465. PMID 18808307. S2CID 86564263.
- ^ Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, et al. (September 2011). "MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin". The Journal of Clinical Endocrinology and Metabolism. 96 (9): 2889–2897. doi:10.1210/jc.2011-1061. PMID 21752880.
- ^ "Targeting Mixed Dyslipidemia and Metabolic Syndrome". Metabolex, Inc. 2005. Archived from the original on 17 October 2006.
- ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
- ^ "Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA" (Press release). Gilead. 14 August 2024. Retrieved 15 August 2024 – via Business Wire.
- ^ Kremer AE, Mayo MJ, Hirschfield GM, Levy C, Bowlus CL, Jones DE, et al. (July 2024). "Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis". Hepatology. 80 (1): 27–37. doi:10.1097/HEP.0000000000000728. PMC 11191048. PMID 38117036.
- ^ a b c "Seladelpar Gilead EPAR". European Medicines Agency (EMA). 12 December 2024. Retrieved 16 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1). hdl:10665/330984.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |